Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.71)
# 3,686
Out of 4,711 analysts
23
Total ratings
26.32%
Success rate
-19.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Reiterates: Overweight | $5 | $0.58 | +762.07% | 2 | Dec 6, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.29 | +287.60% | 2 | Nov 19, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Overweight | $35 | $21.27 | +64.55% | 1 | Nov 18, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $51 | $25.61 | +99.14% | 1 | Nov 18, 2024 | |
| CCCC C4 Therapeutics | Initiates: Equal-Weight | $4 | $3.95 | +1.27% | 1 | Nov 18, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Overweight | $65 | $40.66 | +59.86% | 1 | Nov 18, 2024 | |
| ARVN Arvinas | Initiates: Overweight | $55 | $18.48 | +197.62% | 1 | Nov 18, 2024 | |
| BCYC Bicycle Therapeutics | Initiates: Equal-Weight | $25 | $14.68 | +70.30% | 1 | Nov 8, 2024 | |
| ADCT ADC Therapeutics | Initiates: Overweight | $6 | $1.96 | +206.12% | 1 | Nov 8, 2024 | |
| IMNM Immunome | Initiates: Overweight | $30 | $10.97 | +173.47% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.69 | +669.23% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $29 | $33.29 | -12.89% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $31 | $19.83 | +56.33% | 2 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $11.01 | +127.07% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.45 | +1,011.36% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.84 | +986.96% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $140 | $90.14 | +55.31% | 1 | May 14, 2024 |
Elevation Oncology
Dec 6, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.58
Upside: +762.07%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.29
Upside: +287.60%
Catalyst Pharmaceuticals
Nov 18, 2024
Initiates: Overweight
Price Target: $35
Current: $21.27
Upside: +64.55%
IDEAYA Biosciences
Nov 18, 2024
Initiates: Overweight
Price Target: $51
Current: $25.61
Upside: +99.14%
C4 Therapeutics
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $3.95
Upside: +1.27%
Kymera Therapeutics
Nov 18, 2024
Initiates: Overweight
Price Target: $65
Current: $40.66
Upside: +59.86%
Arvinas
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $18.48
Upside: +197.62%
Bicycle Therapeutics
Nov 8, 2024
Initiates: Equal-Weight
Price Target: $25
Current: $14.68
Upside: +70.30%
ADC Therapeutics
Nov 8, 2024
Initiates: Overweight
Price Target: $6
Current: $1.96
Upside: +206.12%
Immunome
Nov 8, 2024
Initiates: Overweight
Price Target: $30
Current: $10.97
Upside: +173.47%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.69
Upside: +669.23%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $23 → $29
Current: $33.29
Upside: -12.89%
Oct 14, 2024
Reiterates: Overweight
Price Target: $31
Current: $19.83
Upside: +56.33%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $11.01
Upside: +127.07%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.45
Upside: +1,011.36%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.84
Upside: +986.96%
May 14, 2024
Initiates: Overweight
Price Target: $140
Current: $90.14
Upside: +55.31%